Full Press Release Details
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ 11 Metastatic Cutaneous Melanoma.
IDYA
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ 11 Metastatic Cutaneous Melanoma
Key Takeaway: IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ 11 Metastatic Cutaneous Melanoma
Price reaction · baseline $24.99 (2023-10-13 close) · 2 other IDYA headline(s) in the window, move may be shared
day 0 close · peak
-1.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma